A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies

•Bioassay to study complement-mediated damage at myasthenic neuromuscular synapse.•Detailed characterization in situ complement activation at neuromuscular junctions.•Study of complement-activating properties of myasthenia gravis auto-antibodies.•Allows study of complement potency of serum of individual myasthenia gravis patient.•Allows for pre-clinical study of new complement inhibitors.